Log in to search using one of your social media accounts:

 

Broncus Medical affiliate acquires Uptake Medical

Uptake Medical said yesterday that its InterVapor device for treating emphysema is back on the market in Europe after its acquisition for an undisclosed amount by an affiliate of Broncus Medical. Broncus set its purchase up under a new entity based in Seattle, Uptake Medical Technology, and plans to add markets in Australia and Asia to its commercial footprint in Europe by the end of the year. The InterVapor device uses heated water vapor to reduce lung volume in emphysema patients. Uptake won an expanded CE Mark in the European Union for InterVapor in August 2015. “2018 promises to be an exciting year for the new Uptake Medical,” founder &president Robert Barry said in prepared remarks. “With the recent outstanding Step-up multi-center randomized controlled trial results and the backing of Broncus, we are posed for success. In addition, we have very exciting bronchoscopic lung cancer ablation clinical studies underway. When you combine San Jose, Calif.-based Broncus Medical’s Archimedes system for accessing and diagnosing lung disease with [bronchial thermal vapor ablation] you start to see our vision of a complete interventional pulmonology company come to life.” “We also have plans to continue our research of BTVA for emphysema patients and expand the scope of patients that qualify. We are also continuing clinical research and development of our adaptation of the technology for the ablation of several other lung diseases,&r...
Source: Mass Device - Category: Medical Devices Authors: Tags: Mergers & Acquisitions Respiratory Wall Street Beat Broncus Medical Uptake Medical Source Type: news

Related Links:

ConclusionsThis study revealed eight risk factors for fatal AEIP.
Source: Surgery Today - Category: Surgery Source Type: research
Conclusion: Neither of the viruses was found in samples from small-cell, non-small-cell (adenocarcinoma, squamous-cell carcinoma and large-cell neuroendocrine lung cancer), mixed-type and non-differentiated lung carcinoma, and non-cancerous lung tissues (from patients with pneumonia, emphysema and fibrosis).Pathobiology
Source: Pathobiology - Category: Pathology Source Type: research
Chronic obstructive pulmonary disease (COPD) patients are at increased risk of developing nonsmall cell lung carcinoma, irrespective of their smoking history. Although the mechanisms behind this observation are not clear, established drivers of carcinogenesis in COPD include oxidative stress and sustained chronic inflammation. Mitochondria are critical in these two processes and recent evidence links increased oxidative stress in COPD patients to mitochondrial damage. We therefore postulate that mitochondrial damage in COPD patients leads to increased oxidative stress and chronic inflammation, thereby increasing the risk o...
Source: European Respiratory Review - Category: Respiratory Medicine Authors: Tags: COPD and smoking, Mechanisms of lung disease, Lung cancer Reviews Source Type: research
Conclusions Pirfenidone might correlate with a decreased risk of lung cancer in patients with IPF. However, no definite conclusion can be drawn from this retrospective study, and a multicenter, prospective cohort study is still warranted to confirm the effect of pirfenidone on lung cancer in patients with IPF.
Source: Respiratory Investigation - Category: Respiratory Medicine Source Type: research
Authors: Fabre A, Treacy A, Lavelle LP, Narski M, Faheem N, Healy D, Dodd JD, Keane MP, Egan JJ, Jebrak G, Mal H, Butler MW Abstract More data are needed regarding the radiology, co-morbidities and natural history of smoking-related interstitial fibrosis (SRIF), a common pathological finding, mainly described heretofore in association with lung cancer, where respiratory bronchiolitis (RB) usually co-exists. We prospectively acquired high resolution CT scan data (edge-enhancing lung reconstructions) to detect any radiologic interstitial lung abnormality (ILA) in individuals who ultimately underwent surgical lobectom...
Source: COPD: Journal of Chronic Obstructive Pulmonary Disease - Category: Respiratory Medicine Tags: COPD Source Type: research
Conclusion LDCT can detect HS in asymptomatic participants with frequencies similar to previous reports. If liver attenuation is below 40HU and/or L/S ratio below 0.8, further evaluation of HS to the primary care physician or liver specialist is recommended.
Source: European Journal of Radiology - Category: Radiology Source Type: research
Author Affiliations open 1Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada 2Swiss Tropical and Public Health Institute, Basel, Switzerland 3University of Basel, Basel, Switzerland 4Institute for Risk Assessment Sciences, Utrecht University, Utrecht, Netherlands 5MRC-PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK 6National Human Genome Research Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA 7University Medical Center Groningen, Gron...
Source: EHP Research - Category: Environmental Health Authors: Tags: Research Source Type: research
Conclusion: Neither of the viruses was found in samples from small-cell, non-small-cell (adenocarcinoma, squamous-cell carcinoma and large-cell neuroendocrine lung cancer), mixed-type and non-differentiated lung carcinoma, and non-cancerous lung tissues (from patients with pneumonia, emphysema and fibrosis).Pathobiology
Source: Pathobiology - Category: Pathology Source Type: research
Authors: Fourdrain A, De Dominicis F, Lafitte S, Iquille J, Prevot F, Lorne E, Monconduit J, Bagan P, Berna P Abstract BACKGROUND: Predicted postoperative FEV1 (ppoFEV1) must be estimated preoperatively prior to surgery for non-small cell lung cancer (NSCLC). We evaluated a lung volumetry approach based on chest computed tomography (CT). METHODS: A prospective study was conducted over a period of one year in eligible lung cancer patients to evaluate the difference between ppoFEV1 and the 3-month postoperative FEV1 (poFEV1). Patients in whom CT was performed in another hospital and those with factors influencing...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Performance of thoracoscopic pulmonary segmentectomy for primary lung cancer or pulmonary metastases has recently increased. In patients with emphysema, identification of the intersegmental line is often difficult. For non-palpable lesions, securing a sufficient surgical margin is more likely to be uncertain. The purpose of this study was to evaluate the efficacy of intraoperative computed tomography (CT) scan during video-assisted thoracoscopic surgery (VATS) pulmonary segmentectomy.
Source: Seminars in Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Thoracic – Original Submission Source Type: research
More News: Australia Health | Bronchoscopy | Cancer | Cancer & Oncology | China Health | Emphysema | Germany Health | Hong Kong Health | Lung Cancer | Medical Devices | Mergers and Aquisitions | Respiratory Medicine | Study | Venture Capital